Paola Gallinari
Overview
Explore the profile of Paola Gallinari including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
27
Citations
1514
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Fiorentino F, Fabbrizi E, Raucci A, Noce B, Fioravanti R, Valente S, et al.
ChemMedChem
. 2024 Mar;
19(13):e202300655.
PMID: 38529661
Cancer stem cells (CSCs) are a niche of highly tumorigenic cells featuring self-renewal, activation of pluripotency genes, multidrug resistance, and ability to cause cancer relapse. Seven HDACi (1-7), showing either...
2.
Borbely A, Figueras E, Martins A, Bodero L, Raposo Moreira Dias A, Lopez Rivas P, et al.
ChemistryOpen
. 2019 Jul;
8(6):737-742.
PMID: 31275795
RGD-cryptophycin and DGR-cryptophycin conjugates were synthetized by combining peptidomimetic integrin ligands and cryptophycin, a highly potent tubulin-binding antimitotic agent across lysosomally cleavable Val-Ala or uncleavable linkers. The conjugates were able...
3.
Figueras E, Martins A, Borbely A, Le Joncour V, Cordella P, Perego R, et al.
Pharmaceutics
. 2019 May;
11(5).
PMID: 31067748
Tumor targeting has emerged as an advantageous approach to improving the efficacy and safety of cytotoxic agents or radiolabeled ligands that do not preferentially accumulate in the tumor tissue. The...
4.
Borbely A, Figueras E, Martins A, Esposito S, Auciello G, Monteagudo E, et al.
Pharmaceutics
. 2019 Apr;
11(4).
PMID: 30939768
Cryptophycins are potent tubulin polymerization inhibitors with picomolar antiproliferative potency in vitro and activity against multidrug-resistant (MDR) cancer cells. Because of neurotoxic side effects and limited efficacy in vivo, cryptophycin-52...
5.
Yue F, Li W, Zou J, Chen Q, Xu G, Huang H, et al.
Aging (Albany NY)
. 2015 Nov;
7(10):839-53.
PMID: 26540094
Autophagy controls and executes the turnover of abnormally aggregated proteins. MAP1S interacts with the autophagy marker LC3 and positively regulates autophagy flux. HDAC4 associates with the aggregation-prone mutant huntingtin protein...
6.
Gallinari P, Filocamo G, Jones P, Pazzaglia S, Steinkuhler C
Expert Opin Drug Discov
. 2013 Mar;
4(5):525-44.
PMID: 23485085
Background: Hedgehog signaling is essential for the development of most metazoans. In recent years, evidence has accumulated showing that many human tumors aberrantly re-activate this developmental signaling pathway and that...
7.
Paolini C, Orecchia A, Failla C, Gallinari P, Zambruno G, Steinkuhler C
Cancer Invest
. 2013 Jan;
31(1):60-6.
PMID: 23327193
In the development of targeted oncology drugs, it is important to assess drug effectiveness in individual patients. We evaluated the possibility of reproducing in an ex-vivo system the biological effects...
8.
Rotili D, Tarantino D, Nebbioso A, Paolini C, Huidobro C, Lara E, et al.
J Med Chem
. 2012 Nov;
55(24):10937-47.
PMID: 23189967
Chemical changes performed on 1a (sirtinol) led to a series of SIRT1/2 inhibitors, in some cases more potent than 1a mainly against SIRT1. Tested in human leukemia U937 cells, the...
9.
Rotili D, Tarantino D, Carafa V, Paolini C, Schemies J, Jung M, et al.
J Med Chem
. 2012 Aug;
55(18):8193-7.
PMID: 22931526
Inhibition of sirtuins has recently been proposed as a promising anticancer strategy. Some of the new benzodeazaoxaflavins (2a, 2b, and 2d) here reported as SIRT1/2 inhibitors were endowed with pro-apoptotic...
10.
Kinzel O, Alfieri A, Altamura S, Brunetti M, Bufali S, Colaceci F, et al.
Bioorg Med Chem Lett
. 2011 Jul;
21(15):4429-35.
PMID: 21737263
The Hedgehog (Hh-) signaling pathway is a key developmental pathway which gets reactivated in many human tumors, and smoothened (Smo) antagonists are emerging as novel agents for the treatment of...